Janux Therapeutics (JANX) Stock Price, News & Analysis

Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $23.59 to $24.99
• 50-Day Range: $22.62 to $33.20
• 52-Week Range: $22.48 to $71.71
• Volume: 1.29 million shs
• Average Volume: 878,537 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.25
• Consensus Rating: Buy

Janux Therapeutics Stock Analysis - MarketRank™

Janux Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 635th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Janux Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Janux Therapeutics is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Janux Therapeutics is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Janux Therapeutics has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.30% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Janux Therapeutics has recently increased by 19.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Janux Therapeutics does not currently pay a dividend.

Dividend Growth

Janux Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.30% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Janux Therapeutics has recently increased by 19.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.04

News Sentiment

Janux Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Janux Therapeutics this week, compared to 5 articles on an average week.

Search Interest

10 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

6 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Janux Therapeutics insiders have bought 4,323.94% more of their company's stock than they have sold. Specifically, they have bought $13,889,565.00 in company stock and sold $313,964.00 in company stock.

Percentage Held by Insiders

Only 8.10% of the stock of Janux Therapeutics is held by insiders.

Percentage Held by Institutions

75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JANX Stock Analysis - Frequently Asked Questions

How have JANX shares performed this year?

Janux Therapeutics' stock was trading at $53.54 at the beginning of the year. Since then, JANX shares have decreased by 55.7% and is now trading at $23.70.
View the best growth stocks for 2025 here.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) released its earnings results on Thursday, May, 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 463.91%.

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

Who are Janux Therapeutics' major shareholders?

Top institutional investors of Janux Therapeutics include RA Capital Management L.P. (18.91%), Adage Capital Partners GP L.L.C. (6.18%), Paradigm Biocapital Advisors LP (5.63%) and Vanguard Group Inc. (3.85%). Insiders that own company stock include Ra Capital Management, LP, Tighe Reardon, David Alan Campbell, Andrew Hollman Meyer and Ventures Xi LP Avalon.
View institutional ownership trends.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Janux Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JANX
• CIK: 1817713
• Web: www.januxrx.com
• Phone: 858-751-4493
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $95.25
• High Stock Price Target: $200.00
• Low Stock Price Target: $41.00
• Potential Upside/Downside: +301.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.29 million
• Net Margins: -463.91%
• Pretax Margin: -463.91%
• Return on Equity: -10.47%
• Return on Assets: -9.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 38.80
• Quick Ratio: 38.80

Sales & Book Value

• Annual Sales: $9.34 million
• Price / Sales: 150.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.46 per share
• Price / Book: 3.18

Miscellaneous

• Outstanding Shares: 59,175,000
• Free Float: 37,052,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 3.24